Context Therapeutics Inc (CNTX): Net earnings per share growth forecast for next year

Corporate company logo of Context Tx (CNTX)

The expected EPS trajectory for the next 12 months is being adjusted due to geopolitical barriers hindering global therapy trials. The financial stability of Context Therapeutics (CNTX) is based on the success of onapristone and the inflow of investments, while operational processes rely on digital research outsourcing. The value of 13.30 shows the current metric value, determining market expectations for the company's profit.

CNTX: Context Tx Expected earnings per share growth for next year 07/04/2022 - 11/15/2026

Analytical breakdowns for Context Therapeutics (CNTX)

- share price and consensus valuation forecast:
Stock Price Context Therapeutics Inc|CNTX - Average Forecast Price
- stock exchange capitalization data:
Market Value CNTX|CNTX - Business Value
- company book value details:
Book Value per Share Context Therapeutics|CNTX - Company Net Assets|Market Value to Book Value Ratio contexttherapeutics.com|CNTX - Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Context Therapeutics|CNTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Context Therapeutics Inc|CNTX - Company Cumulative Indebtedness|Debts to Book Capitalization Context Therapeutics|CNTX - Long-Term Debt|Company Current Liabilities Context Therapeutics|Quick Liquidity Indicator contexttherapeutics.com
- earnings and valuation multiples information:
CNTX - Profit After Payment of Taxes|Future Profit Context Therapeutics|CNTX - Company Value to Net Income|Projected Price to Earnings Context Therapeutics Inc|CNTX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Context Tx|CNTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Context Therapeutics|CNTX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months contexttherapeutics.com|CNTX - Earnings per share increase in current year|Earnings growth forecast for next year Context Therapeutics
- sales volume and revenue indicators:
CNTX - Revenue and Sales Volume|Company Projected Revenue Context Tx|CNTX - Price-to-Sales Ratio|Forward P/S Multiple Context Therapeutics|CNTX - Trailing Twelve Months Revenue Growth
Fundamental valuation:Context Therapeutics, CNTX
Core merchandise of Context Tx

A conservative approach to analyzing Context Therapeutics (CNTX) requires separating market emotions from mathematical return forecasts. This indicator measures expert consensus expectations for forward-looking earnings changes, capturing every refinement of the growth model. The trend in analysts' net income estimates for year n+1 reflects the probability of onapristone's commercial success and the company's ability to secure funding for the final stages of drug registration.

Competitors of Context Therapeutics

MRUS (Merus NV) - Earnings growth forecast for next year|Expected net earnings per share growth next year immutep.com IMMP|Net earnings per share growth forecast for next year Anixa Biosciences Inc (ANIX)|Atossa Therapeutics, Inc. - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Mersana Therapeutics MRSN|BriaCell Corp - Net earnings per share growth forecast for next year|EPIX - Net earnings per share growth forecast for next year|Expected earnings per share trend next year QTI (QT Imaging Holdings, Inc.)